GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 60 Degrees Pharmaceuticals Inc (NAS:SXTP) » Definitions » Interest Expense

SXTP (60 Degrees Pharmaceuticals) Interest Expense : $-0.01 Mil (TTM As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is 60 Degrees Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. 60 Degrees Pharmaceuticals's interest expense for the three months ended in Sep. 2024 was $ -0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.01 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. 60 Degrees Pharmaceuticals's Operating Income for the three months ended in Sep. 2024 was $ -2.12 Mil. 60 Degrees Pharmaceuticals's Interest Expense for the three months ended in Sep. 2024 was $ -0.00 Mil. 60 Degrees Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

60 Degrees Pharmaceuticals Interest Expense Historical Data

The historical data trend for 60 Degrees Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

60 Degrees Pharmaceuticals Interest Expense Chart

60 Degrees Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Interest Expense
-2.68 -3.17 -3.99 -2.29

60 Degrees Pharmaceuticals Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 -0.01 - - -

60 Degrees Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

60 Degrees Pharmaceuticals  (NAS:SXTP) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

60 Degrees Pharmaceuticals's Interest Expense for the three months ended in Sep. 2024 was $-0.00 Mil. Its Operating Income for the three months ended in Sep. 2024 was $-2.12 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2024 was $0.15 Mil.

60 Degrees Pharmaceuticals's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as

60 Degrees Pharmaceuticals did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

60 Degrees Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 60 Degrees Pharmaceuticals Inc (NAS:SXTP) » Definitions » Interest Expense
Comparable Companies
ACUT GNPX TTNP WINT MTNB AGTX LIXT QRON EYEN GRTX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
1025 Connecticut Avenue NW, Suite 1000, Washington, D.C, WA, USA, 20036
Website
https://www.60degreespharma.com
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
Executives
Cheryl Xu director 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Geoffrey S Dow director, 10 percent owner, officer: CEO and President 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Charles W Allen director 1881 N. NASH STREET, UNIT 701, ARLINGTON VA 22209
Kentucky Technology Inc. 10 percent owner 824 BULL LEA RUN, SUITE 2100, LEXINGTON KY 40511
Paul Field director 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Tyrone Miller officer: Chief Financial Officer 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Florida State University Research Foundation Inc. 10 percent owner 200 LEVY AVENUE, BUILDING A, SUITE 351, TALLAHASSEE FL 32310
Bryan Lee Smith officer: Chief Medical Officer 1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Stephen Toovey director 1025 CONNECTICUT AVENUE NW, SUITE 100, WASHINGTON DC 20036